We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 137

Impeachment action in respect of expired patent allowed to continue

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • December 17 2012

Apotex commenced an impeachment action in respect of two patents. Warner-Lambert brought a motion seeking to dismiss the action as it related to one patent

Merck leave to appeal to SCC dismissed

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • June 18 2012

The Supreme Court of Canada dismissed Merck’s application for leave to appeal, with costs to Apotex

Ontario Court dismisses generic claims for unjust enrichment in s. 8 proceeding

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • January 30 2013

Apotex sued Abbott and Takeda for damages pursuant to s. 8 of the NOC Regulations. As part of the claim, Apotex claimed disgorgement of profits

Intellectual property weekly abstracts bulletin

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • April 1 2013

The Court granted a Prohibition Order to AstraZeneca, preventing Ranbaxy from entering the market with a generic version of ompeprazole until the

Appeal of the re-examination board’s decision dismissed: three claims rejected

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • April 4 2014

This was an appeal of a decision of a Re-Examination Board cancelling three claims of Newco Tank Corp.’s (“Newco”) Canadian Patent No. 2,421,384 (the

Other industry news

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • April 30 2014

The PMPRB has published a new analytical report: Utilization of Prescription Opioids in Canada's Public Drug Plans, 200607 to 201213

Supreme Court denies Apotex leave to appeal; prohibition order stands

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • April 30 2014

The Supreme Court of Canada (SCC) denied Apotex leave to Appeal the decision of the Federal Court of Appeal (FCA) in a s. 8 case (decision here

Oder of prohibition issues no promise to treatment in humans or reduced side effects was found

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • April 30 2014

Pfizer’s Canadian Patent No. 2,177,576 for Celebrex has withstood Apotex’s allegations and was found to be valid; therefore the Minister is

Other industry news

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • October 27 2010

The Government has published amendments to the Patented Medicines (Notice of Compliance) Regulations

The Court of Appeal sends s.8 case back to trial judge for redetermination

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • March 26 2012

The Federal Court of Appeal (FCA) has granted Apotex’ appeal and sent a case considering s. 8 of the Patented Medicines (Notice of Compliance) Regulations (the Regulations) back to the Trial Judge for redetermination